On May 15, 2014, Kramer Levin client PBM Pharmaceuticals, Inc. (“PBM”) completed its sale of Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome and acute enterocolitis, to Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp., for US $200 million in cash and an aggregate of 4,605,833 common shares of Concordia Healthcare Corp.  PBM, a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals, specializes in selling, distributing, marketing and manufacturing prescription products that help improve patients’ health and quality of life.

The Kramer Levin team that represented PBM was led by corporate partners Steven M. Goldman and James A. Grayer and associate Joshua S. Goldman.  Additional team members included intellectual property partners Erica D. Klein and Paul J. Andre, tax partner Howard J. Rothman and special counsel Blake A. Rigel.

Related People